Patient-derived cell line, xenograft and organoid models in lung cancer therapy.
Ontology highlight
ABSTRACT: Lung cancer accounts for most cancer-related deaths worldwide and has an overall 5-year survival rate of ~15%. Cell lines have played important roles in the study of cancer biology and potential therapeutic targets, as well as pre-clinical testing of novel drugs. However, most experimental therapies that have cleared preclinical testing using established cell lines have failed phase III clinical trials. This suggests that such models may not adequately recapitulate patient tumor biology and clinical outcome predictions. Here, we discuss and compare different pre-clinical lung cancer models, including established cell lines, patient-derived cell lines, xenografts and organoids, summarize the methodology for generating these models, and review their relative advantages and limitations in dif
SUBMITTER: Huo KG
PROVIDER: S-EPMC7653147 | biostudies-literature | 2020 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA